August 27, 2015

FDA lays out proposal for naming lower-cost biotech drugs -- Santa Fe New Mexican/Associated Press

The Food and Drug Administration released its proposal Thursday for naming lower-cost biotech drugs, a critical step in creating a market for the new class of medicines.

These quasi-generic biotech drugs have the potential to save the U.S. health care system billions of dollars in costs. But representatives for the generic drug industry warned that the FDA's proposal could curb those savings by making the drugs more difficult to prescribe. -- 8/27/2015